Display options
Cite
Richardson H, Johnston D, Pater J, et al. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007;14(3):89-96doi: 10.3747/co.2007.117.
Richardson, H., Johnston, D., Pater, J., & Goss, P. (2007). The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Current oncology (Toronto, Ont.), 14(3), 89-96. https://doi.org/10.3747/co.2007.117
Richardson, H, et al. "The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial." Current oncology (Toronto, Ont.) vol. 14,3 (2007): 89-96. doi: https://doi.org/10.3747/co.2007.117
Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117. PMID: 17593981; PMCID: PMC1899358.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117.

The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.

Current oncology (Toronto, Ont.)

H Richardson, D Johnston, J Pater, P Goss

Affiliations

  1. National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario.

PMID: 17593981 PMCID: PMC1899358 DOI: 10.3747/co.2007.117

Abstract

Several large phase III trials have demonstrated that tamoxifen-and more recently, raloxifene-can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has developed a randomized phase III study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The NCIC CTG map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene.

References

  1. J Clin Oncol. 2000 Apr;18(7):1399-411 - PubMed
  2. Lancet. 2002 Sep 14;360(9336):817-24 - PubMed
  3. J Natl Cancer Inst Monogr. 2001;(30):5-15 - PubMed
  4. J Natl Cancer Inst. 2006 Dec 6;98(23):1673-5 - PubMed
  5. N Engl J Med. 2005 Mar 17;352(11):1092-102 - PubMed
  6. Eur J Cancer. 2000 May;36(8):976-82 - PubMed
  7. N Engl J Med. 2007 Apr 19;356(16):1670-4 - PubMed
  8. CA Cancer J Clin. 1999 May-Jun;49(3):138-44 - PubMed
  9. J Natl Cancer Inst. 1996 Mar 6;88(5):291-6 - PubMed
  10. JAMA. 2006 Jun 21;295(23):2727-41 - PubMed
  11. Carcinogenesis. 1994 Dec;15(12):2775-80 - PubMed
  12. Lancet. 2002 Jun 22;359(9324):2131-9 - PubMed
  13. J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 - PubMed
  14. J Natl Cancer Inst. 2005 May 18;97(10):755-65 - PubMed
  15. J Clin Oncol. 1999 Sep;17(9):2659-69 - PubMed
  16. J Clin Oncol. 2006 Nov 20;24(33):5305-12 - PubMed
  17. J Clin Oncol. 2002 Aug 1;20(15):3328-43 - PubMed
  18. N Engl J Med. 1997 May 15;336(20):1401-8 - PubMed
  19. Lancet. 2007 Feb 17;369(9561):559-70 - PubMed
  20. Ann Epidemiol. 2006 Mar;16(3):230-40 - PubMed
  21. J Clin Oncol. 1996 Jul;14(7):2000-11 - PubMed
  22. J Clin Oncol. 2005 Jan 20;23(3):619-29 - PubMed
  23. J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 - PubMed
  24. JAMA. 1993 Jul 21;270(3):338-43 - PubMed
  25. Arch Intern Med. 2004 Sep 27;164(17):1897-903 - PubMed
  26. J Gen Intern Med. 2004 Apr;19(4):302-9 - PubMed
  27. Br J Cancer. 1995 Jul;72(1):72-5 - PubMed
  28. J Natl Cancer Inst. 2007 Feb 21;99(4):272-82 - PubMed
  29. Br J Cancer. 2001 May 4;84(9):1188-92 - PubMed
  30. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):633-6 - PubMed
  31. Cancer Res. 2006 Feb 15;66(4):2476-82 - PubMed
  32. Clin Breast Cancer. 2006 Feb;6 Suppl 2:S58-64 - PubMed
  33. JAMA. 2002 Jul 17;288(3):321-33 - PubMed
  34. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73 - PubMed
  35. FEBS Lett. 1993 Sep 13;330(2):156-60 - PubMed
  36. J Clin Oncol. 1998 Feb;16(2):453-61 - PubMed
  37. J Natl Cancer Inst. 1999 Apr 7;91(7):579-81 - PubMed
  38. N Engl J Med. 2005 Dec 29;353(26):2747-57 - PubMed
  39. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71 - PubMed
  40. Eur J Cancer. 1992;28A(6-7):1148-53 - PubMed
  41. Prev Med. 2005 Jul;41(1):7-15 - PubMed
  42. J Natl Cancer Inst. 1995 May 3;87(9):670-5 - PubMed
  43. Drugs. 1999 Oct;58(4):675-80; discussion 681-2 - PubMed
  44. Cancer Res. 1996 Nov 15;56(22):5125-7 - PubMed
  45. J Clin Oncol. 2006 Nov 20;24(33):e49-50 - PubMed
  46. N Engl J Med. 2001 Jan 25;344(4):276-85 - PubMed
  47. Cancer Genet Cytogenet. 1986 Aug;22(4):369-71 - PubMed
  48. J Natl Cancer Inst. 2005 May 18;97(10):715-23 - PubMed
  49. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 - PubMed
  50. Ann Surg Oncol. 2001 Aug;8(7):580-5 - PubMed
  51. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1021-7 - PubMed
  52. Prog Clin Biol Res. 1996;394:xiii-xix, 1-479 - PubMed
  53. J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 - PubMed
  54. Arch Intern Med. 2006 Nov 13;166(20):2260-5 - PubMed
  55. J Gen Intern Med. 2006 Jul;21(7):779-85 - PubMed
  56. Ann Fam Med. 2005 May-Jun;3(3):242-7 - PubMed
  57. J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15 - PubMed
  58. N Engl J Med. 2003 Nov 6;349(19):1793-802 - PubMed
  59. J Natl Cancer Inst. 2004 Sep 1;96(17):1276-87 - PubMed
  60. Environ Health Perspect. 1999 Feb;107 Suppl 1:145-54 - PubMed
  61. N Engl J Med. 2005 Mar 17;352(11):1071-80 - PubMed
  62. Breast Cancer Res. 2005;7(5):R833-43 - PubMed

Publication Types